IDEXX Laboratories Slashes FY22 Outlook - Update
(RTTNews) - While reporting financial results for the second quarter on Tuesday, pet healthcare provider IDEXX Laboratories, Inc. (IDXX) slashed its earnings and revenue growth guidance for the full-year 2022.
For fiscal 2022, the company now projects earnings in a range of $7.77 to $8.05 per share on revenues between $3.305 billion and $3.385 billion, with revenue growth of 3 to 5.5 percent and organic revenue growth of 5.5 to 8 percent.
Previously, the company expected earnings in a range of $8.11 to $8.35 per share on revenue growth of 5.5 to 8 percent and organic revenue growth of 7.5 to 10 percent.
On average, 11 analysts polled by Thomson Reuters expect the company to report earnings of $8.27 per share on revenues of $3.42 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
IDEXX Laboratories Slashes FY24 Outlook - Update
IDEXX Labs Launch First Veterinary Diagnostic Test To Detect Kidney Injury In Cats And Dogs
U.S. Dollar Drops After Powell's Speech
TSX Hits New Record High As Stocks Rally On Fed Rate Cut Hopes
Powell Says Outlook, Shifting Balance Of Risks 'May Warrant' Lower Rates
Bay Street Likely To Open On Mixed Note; Powell's Speech Eyed
Sensex, Nifty Snap Six-day Winning Streak On Tariff Concerns
